Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC)
Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC)
Recruiting · NCT06923826 · Registry updated 2025-07-25Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC) | Head and Neck Neoplasms, Mouth Neoplasms, Neoplasms by Site, Stomatognathic Diseases, endocrine system disorder, malignant endocrine neoplasm, mouth disorder, neoplasm, salivary gland cancer, salivary gland disorder, thyroid gland disorder, thyroid tumor | Recruiting | Phase 2 | 2025-07-25 | NCT06923826 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Gilead Sciences | 180 |
| National University Hospital, Singapore | 120 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| National University Cancer Institute Singapore | Singapore | Singapore | 1 |